Inhibition of Vasopressin Action in
an important physiological role in vasoconstric-.Z \ . tion and antidiuresis. Classically, two classes of AVP receptors have been identified. 1 The V! receptor, which has been described in vascular smooth muscle and liver, signals through increases in intracellular Ca 2+ ; the V 2 receptor, which has been described in the kidney, signals through increases in cyclic AMP. Both of these receptors have been cloned recently 2 -3 and belong to the family of "seven membrane spanning" receptors, which signal through G proteins. In vascular smooth muscle cells (VSMCs), acute stimulation by AVP results in a rapid contraction of the cells/ Prolonged AVP stimulation of VSMCs in the absence of other growth-promoting agents has been shown to cause hypertrophy. 5 Although a number of postreceptor signaling events regulated by AVP have been described, the mechanisms of AVP-induced contraction and hypertrophy have not been clearly delineated.
In VSMCs, AVP acting through a pertussis-insensitive G protein causes activation of phosphatidylinositol-specific phospholipase C-/3, 6 which mobilizes intracellular Ca 2 * 4 ' 7 -8 and through the production of diacylglycerol activates protein kinase C. Increases in intracellular Ca 2+ , through the action of calmodulin, activate myosin light chain kinase, which in turn phosphorylates myosin light chain, 9 a critical event in the early phase of contraction. Recently it has been shown that AVP and other vasocon-strictors induce the activation of p42/44 mitogen-activated protein kinase (MAP kinase).
1014 p42/44 MAP kinases are members of a family of serine-threonine protein kinases that are themselves activated by phosphorylation on tyrosine and threonine residues. These kinases are activated by growth factors and are believed to play a critical role in cell proliferation (for a recent review, see Reference 15) .
A number of specific AVP analogues have been described. 16 These molecules are all peptides, and thus their clinical efficacy is likely to be limited to parenteral administration. Recently, Yamamura et al' 7 identified an orally active, nonpeptide V, antagonist, OPC-21268. This agent selectively inhibited AVP binding in rat liver plasma membranes. In the present study we have examined the potency of this agent to inhibit AVP binding and postreceptor signaling events in cultures of rat aortic VSMCs.
Methods Materials
The V, antagonist OPC-21268 (l-{l- Probes Inc (Eugene, Ore). Bradford protein assay kit was obtained from Bio-Rad (Richmond, Calif).
Vascular Smooth Muscle Cell Culture
Rat aortic VSMCs were isolated and cultured as previously described in detail. 418 Briefly, under sterile conditions, aortas were resected from male Sprague-Dawley rats (200 to 300 g) and cleaned of adventitia and connective tissue. The vessels were chopped and incubated for 2 hours in Eagle's MEM containing 2.4 mg/mL collagenase. The resulting cell suspension was plated on 35-mm dishes and grown in Eagle's MEM containing 2 mmol/L L-glutamine, 2 g/L NaHCO 3 ,100 IU/mL penicillin, 100 mg/L streptomycin, and 10% fetal calf serum at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Cells were passaged using trypsin-EDTA. Cells (passages 1 through 9) were grown to confluence and serum-restricted 20 hours before study. For studies measuring intracellular Ca 2+ , cells were grown on glass coverslips. 
Receptor Binding

Calcium Efflux
43
Ca efflux was determined by a method similar to that previously described.
19
- 20 The culture medium was aspirated and cells were washed twice with 2 mL physiological salt solution (PSS) (mmol/L: NaCl, 140; KC1, 4.6; MgCl 2 , 1.0; CaCl 2 , 2.0; glucose, 10; HEPES, 10, pH 7.4). Cells were loaded with 5 mCi 45 Ca in 1 mL PSS for 2 hours at 37°C. At the end of the incubation, cells were rinsed 10 times rapidly with 1 mL PSS and 1 mL fresh PSS added. The PSS was removed at 1-minute intervals and replaced with fresh buffer for 4 minutes. At 4 and 5 minutes, buffer was replaced with PSS containing various concentrations of OPC-21268. At 6 minutes, buffer was replaced with PSS containing AVP or vehicle and OPC-21268. After the addition of AVP, buffer was removed at 2-minute intervals and replaced with fresh PSS. At 14 minutes, the cell pellets were solubilized with 0.1% sodium dodecyl sulfate in 0.1N NaOH. Buffer samples and solubilized cells were collected in vials for liquid scintillation counting. "Ca released from the cells was expressed as a percentage of total available cellular radioactivity (counts released after AVP addition plus counts in solubilized cell pellet). indicator fura 2 using video imaging. VSMCs were grown on No. 1 glass coverslips and loaded with 5 mmol/L fura 2-AM in the presence of the nonionic detergent pluronic (0.025%) at 37°C for 30 minutes. The VSMCs then were washed to remove extracellular fura 2-AM. OPC-21268 was added 2 minutes before the addition of AVP (10~8 mol/L). Fluorescence in individual cells was measured and analyzed with a customized imaging system (S&M Microscopes, Colorado Springs, Colo).
Quantitation of Intracellular Free
The coverslip was mounted in an open chamber on the stage of an inverted microscope (Diaphot, Nikon, Garden City, NY) equipped for epifluorescence microscopy. The VSMCs were illuminated by a 75-W xenon lamp alternately with a 340-and 380-nm excitation filter (340DF20 and 380DF10, Omega Optical Inc, Brattleboro, Vt) and a 400-nm dichroic mirror (DM 400, Nikon). These excitation filters were changed using a computer-controlled filter wheel (Imec, Charlestown, Mass). Emitted light was collected through the dichroic mirror, transmitted through a 510-nm filter (510 DF20, Omega Optical), and imaged onto the face of an intensified charge-coupled device camera (Genisys Intensifier, CCD72 camera, Dage-MTI, Inc, Michigan City, Ind). The images were processed through an IBM PC/AT computer using an image-processing program (Image 1/Fluor, Universal Imaging Corp, West Chester, Pa). Autofluorescence measured in unloaded cells was less than 2% of the fura 2 signal. The maximal ratio was measured after addition of 10 mmol/L ionomycin and the minimal ratio after subsequent addition of 10 mmol/L Tris-EGTA. [Ca 2+ ], was calculated using the formula of Grynkiewicz, 22 with an estimated
Mitogen-Activated Protein Kinase Activity
Cells were pretreated for 2 minutes in Eagle's MEM with various concentrations of OPC-21268 and then stimulated with 10" 8 mol/L AVP for 5 minutes at 37°C. Stimulation was stopped by aspirating the media. Cells were rinsed twice with ice-cold phosphate-buffered saline and lysed by the addition of 0.25 mL lysis buffer (mmol/L: /3-glycerophosphate, 50; Na 3 VO 4 , 0.1; MgCl 2 , 2.0; EGTA 1-0; dithiothreitol, 1.0; pepstatin, 0.02; leupeptin, 0.02; PMSF, 1; as well as 0.5% [wt/vol] Triton X-100 and 1000 U/mL aprotinin, pH 7.2). Lysed cells were centrifuged for 10 minutes at 12 OOOg. Supernatants were assayed for MAP kinase activity by phosphorylation of MBP using a modification of the method previously described. 11 The assay was performed at 30°C for 15 minutes in a final volume of 40 jtL containing (final concentration) 12.5 mmol/L MgCl 2 , 50 ^tg/mL protein kinase inhibitor peptide, 1 mg/mL MBP, and 50 mmol/L [-y- 
Statistical Analysis
Results are expressed as mean±SEM. Differences between means were evaluated by ANOVA with the Newman-Keuls multiple-comparisons procedure. A value of P<.05 was taken to be significant.
Results
Vasopressin Binding
The ability of the V, antagonist OPC-21268 to inhibit [ 7 mol/L OPC-21268, and complete inhibition occurred at 10" 6 mol/L antagonist. These higher OPC-21268 concentrations (10~7 or 10" 6 mol/L) also appeared to increase the time required after AVP addition to reach maximal [Ca 2+ ], (Fig 3) .
Mitogen-Activated Protein Kinase
We next examined the ability of the V, antagonist to inhibit AVP-induced activation of MAP kinase. After stimulation of cells with 10" 8 mol/L AVP, cell lysates were prepared and assayed for MAP kinase using the specific substrate MBP, as previously described. 1114 As Discussion The V, isoform of the AVP receptor is believed to be the major form present in vascular smooth muscle and to mediate the effects of AVP on cell contraction and hypertrophy. The receptor subtypes in these cells have not been clearly delineated. In the present studies we have shown that a nonpeptide specific V, antagonist, OPC-21268, blocks both AVP binding and postreceptor signaling events in cultured aortic VSMCs. A specific V 2 antagonist was ineffective in blocking these effects. The potency of OPC-21268 in blocking specific [ 3 H]AVP binding was similar to that of specific peptide W t antagonists used in earlier studies. 16 Binding inhibition occurred at much lower concentrations than observed in binding to liver membranes. 17 OPC-21268 also specifically blocked two postreceptor signaling events stimulated by AVP: increases in intracellular Ca 2+ and activation of MAP kinase. AVPinduced increases in intracellular Ca 2+ were measured using two techniques:
45 Ca 2+ efflux and increases in [Ca 2+ ]i using fura 2. Both techniques gave the same results, requiring 20 to 50 times higher concentrations of antagonist to half-maximally block Ca 2+ increases than to half-maximally inhibit binding. These data suggest the existence of "spare" receptors. In this model maximal increases in intracellular Ca 2+ occur when only a small number of AVP receptors are occupied. High concentrations of antagonist thus are required to block AVP binding to most of the receptors before inhibition of postreceptor events is detected. Previous studies have examined the AVP dose response for increasing intracellular Ca 2+ in VSMCs. Half-maximal stimulation was obtained at 5xlO"' 7 to 5X10- (Fig 5) . These data suggest that increases in intracellular Ca 2+ are not required for MAP kinase activation and are consistent with earlier studies showing that activation of protein kinase C was both necessary and sufficient for MAP kinase activation.
14 These data are also consistent with the concept of "spare" receptors for MAP kinase activation. The AVP dose-response curve for MAP kinase activation is shifted to the left compared with AVP binding, with half-maximal activation occurring at approximately 10" 10 mol/L AVP." Therefore, maximal MAP kinase activation is achieved at low receptor occupancy, presumably through sufficient diglyceride production to maximally activate protein kinase C.
An alternative model to "spare" receptors that could account for the differential effects of OPC-21268 is the existence of multiple subtypes of V, receptors with similar affinities for AVP but different affinities for OPC-21268. One subtype would be coupled to increases in intracellular Ca 2+ and activation of MAP kinase and would have a low affinity for OPC-21268. The second subtype with higher affinity for the antagonist would be coupled to as yet unidentified second messenger systems or act as a clearance receptor for AVP in vascular smooth muscle. Analysis of the binding displacement (Fig 1) by a curve-fitting program did not allow us to distinguish between a one-site or two-site model. Further testing of multiple binding sites for OPC-21268 will require binding studies using radiolabeled antagonist. It should be noted that polymerase chain reactions using RNA from rat liver and oligonucleotides derived from the published sequence of the V[ receptor yield multiple bands (L.E. Heasley, personal communication), suggesting the existence of multiple isoforms of the V( receptor. OPC-21268 may prove to be a valuable reagent in identifying these novel subtypes and establishing their physiological role. It is also possible that pretreatment of VSMCs with OPC-21268 results in internalization of a portion of the AVP receptors, with higher concentrations of antagonists required to inhibit the receptors remaining at the cell surface. Examination of this will require binding studies using radiolabeled OPC-21268.
The existence of receptor subtypes with differential affinity for nonpeptide antagonists has been demonstrated for angiotensin II: DuP 753 shows selectivity for the AT, receptor and PD 123177 for the AT 2 receptor (see Reference 26 for review). Interestingly, both subtypes have been shown to exist in the same tissue, and the physiological role of the AT 2 receptor remains to be established.
In summary, we have shown that OPC-21268 selectively inhibits AVP binding and postreceptor signaling in VSMCs with different potencies. The ability of certain concentrations of OPC-21268 to selectively block certain postreceptor events will be a powerful tool in dissecting the specific events required to mediate AVP-induced contraction versus hypertrophy in these cells. These data also suggest that the dose of this drug used clinically will be a critical determinant in obtaining therapeutic effects.
